Welcome back to Endpoints Weekly! We unveiled our 2026 Women in Biopharma special project on Monday. Our team pored through nearly 200 nominations to reach this year’s list of 20 ...
Pancreatic cancer patients with the most common KRAS mutation appeared to have a lower response rate than the overall patient ...
City Therapeutics eyes $158M IPO; Iambic Therapeutics targets $135M; Alchemist Capital launches with $100M; Life Biosciences ...
Curium prices Bexlutry, its copycat of Novartis’ radioligand Lutathera, at $63,524 per infusion, about 5% below the original.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results